The Review of Anti-aging Mechanism of Polyphenols on Caenorhabditis elegans.
L Liu, P Guo, P Wang, S Zheng, Z Qu, et al. 2021. PMID: 34327192 PMCID: PMC8314386 DOI: 10.3389/fbioe.2021.635768
Caenorhabditis elegans as a Useful Model for Studying Aging Mutations.
S Zhang, F Li, T Zhou, G Wang, Z Li. 2020. PMID: 33123086 PMCID: PMC7570440 DOI: 10.3389/fendo.2020.554994
Caenorhabditis elegans as a model system for studying aging-associated neurodegenerative diseases.
KM Van Pelt, MC Truttmann. 2020. PMID: 34327290 PMCID: PMC8317484 DOI: 10.1016/j.tma.2020.05.001
J Alvarez, P Alvarez-Illera, P García-Casas, RI Fonteriz, et al. 2020. PMID: 31947609 PMCID: PMC7016793 DOI: 10.3390/cells9010204
Y Ye, Q Gu, X Sun, et al. 2020. PMID: 33337057 DOI: 10.1111/1541-4337.12654
TOR Signaling in Caenorhabditis elegans Development, Metabolism, and Aging.
TK Blackwell, AK Sewell, Z Wu, M Han. 2019. PMID: 31594908 PMCID: PMC6781902 DOI: 10.1534/genetics.119.302504
Age‐dependent changes and biomarkers of aging in Caenorhabditis elegans.
HG Son, O Altintas, EJE Kim, S Kwon, SJV Lee. 2019. PMID: 30734981 PMCID: PMC6413654 DOI: 10.1111/acel.12853
A living model for obesity and aging research: Caenorhabditis elegans.
P Shen, Y Yue, Y Park. 2018. PMID: 27575804 DOI: 10.1080/10408398.2016.1220914
The nematode Caenorhabditis elegans as a model for aging research.
HI Mack, T Heimbucher, CT Murphy. 2018. DOI: 10.1016/j.ddmod.2018.11.001
P Shen, Y Yue, J Zheng, Y Park. 2018. PMID: 29261338 DOI: 10.1146/annurev-food-030117-012709
Exposome, Molecular Pathways and One Health: The Invertebrate Caenorhabditis elegans.
A von Mikecz. 2022. PMID: 36012346 PMCID: PMC9409025 DOI: 10.3390/ijms23169084
Caenorhabditis elegans: a nature present for advanced food science.
Y Li, Y Wang, P Li, Q Zhou, X Zheng, Q Gu. 2022. DOI: 10.1016/j.cofs.2022.100971
The role of miR-23b in cancer and autoimmune disease.
YX Guo, N Wang, WC Wu, CQ Li, RH Chen et al. 2021. PMID: 34777498 PMCID: PMC8580694 DOI: 10.1155/2021/6473038
The role of miRNAs in the regulation of autophagy in autoimmune diseases.
S Khodakarimi, A Zarebkohan, H Kahroba, M Omrani, et al. 2021. PMID: 34144058 DOI: 10.1016/j.lfs.2021.119726
Therapies targeting trained immune cells in inflammatory and autoimmune diseases.
C Municio, G Criado. 2021. PMID: 33569065 PMCID: PMC7868395 DOI: 10.3389/fimmu.2020.631743
MAP4K3/GLK in autoimmune disease, cancer and aging.
HC Chuang, TH Tan. 2019. PMID: 31640697 PMCID: PMC6806545 DOI: 10.1186/s12929-019-0570-5
Emerging roles of noncoding RNAs in T cell differentiation and functions in autoimmune diseases.
S Roy, A Awasthi. 2019. PMID: 31411520 DOI: 10.1080/08830185.2019.1648454
Efferocytosis and autoimmune disease.
M Kawano, S Nagata. 2018. PMID: 30165442 PMCID: PMC6234909 DOI: 10.1093/intimm/dxy055
Dysregulation of microRNAs in autoimmune diseases: pathogenesis, biomarkers and potential therapeutic targets.
H Long, X Wang, Y Chen, L Wang, M Zhao, Q Lu. 2018. PMID: 29680223 DOI: 10.1016/j.canlet.2018.04.016
The role of efferocytosis in autoimmune diseases.
F Abdolmaleki, N Farahani, SM Gheibi Hayat, et al. 2018. PMID: 30083153 PMCID: PMC6064952 DOI: 10.3389/fimmu.2018.01645
C. elegans as a Powerful Tool for Cancer Screening.
E di Luccio, M Morishita, T Hirotsu. 2022. PMID: 36289633 PMCID: PMC9598459 DOI: 10.3390/biomedicines10102371
The roles of the Let-7 family of MicroRNAs in the regulation of cancer stemness.
Y Ma, N Shen, MS Wicha, M Luo. 2021. PMID: 34572067 PMCID: PMC8469079 DOI: 10.3390/cells10092415
Analysis of mutational signatures in C. elegans: implications for cancer genome analysis.
B Meier, NV Volkova, M Gerstung, A Gartner. 2020. PMID: 32980770 DOI: 10.1016/j.dnarep.2020.102957
PD-1: its discovery, involvement in cancer immunotherapy, and beyond.
Y Ishida. 2020. PMID: 32492969 PMCID: PMC7349669 DOI: 10.3390/cells9061376
Development of an early cancer detection method using the olfaction of the nematode Caenorhabditis elegans.
T Uozumi, T Hirotsu, et al. 2019. PMID: 31061346 DOI: 10.1248/yakushi.18-00185-4
Multiple functions of DYRK2 in cancer and tissue development.
S Yoshida, K Yoshida. 2019. PMID: 31505048 DOI: 10.1002/1873-3468.13601
MAP4K3/GLK in autoimmune disease, cancer and aging.
HC Chuang, TH Tan. 2019. PMID: 31640697 PMCID: PMC6806545 DOI: 10.1186/s12929-019-0570-5
Cell motility in cancer invasion and metastasis: insights from simple model organisms.
CH Stuelten, CA Parent, DJ Montell. 2018.
MicroRNAs and cancer: a long story for short RNAs.
A Drusco, CM Croce. 2017. PMID: 28882219 DOI: 10.1016/bs.acr.2017.06.005
The Review of Anti-aging Mechanism of Polyphenols on Caenorhabditis elegans.
L Liu, P Guo, P Wang, S Zheng, Z Qu, et al. 2021. PMID: 34327192 PMCID: PMC8314386 DOI: 10.3389/fbioe.2021.635768
Mitochondrial quality control in the heart: new drug targets for cardiovascular disease.
CM Oh, D Ryu, S Cho, Y Jang. 2020. PMID: 32216174 PMCID: PMC7098821 DOI: 10.4070/kcj.2019.0416
The Nematode Caenorhabditis elegans as a Model Organism to Study Metabolic Effects of ω-3 Polyunsaturated Fatty Acids in Obesity.
A Bouyanfif, S Jayarathne, I Koboziev, et al. 2019. PMID: 30689684 PMCID: PMC6370270 DOI: 10.1093/advances/nmy059
miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges.
S Zhou, J Jin, J Wang, Z Zhang, JH Freedman, et al. 2018. PMID: 29877320 PMCID: PMC6289363 DOI: 10.1038/aps.2018.30
Targeting autophagy in aging and aging-related cardiovascular diseases.
J Ren, Y Zhang. 2018. PMID: 30458935 PMCID: PMC6251315 DOI: 10.1016/j.tips.2018.10.005
Role of miRNAs on the Pathophysiology of Cardiovascular Diseases.
KC Almeida, C Fernandes-Santos. 2018. PMID: 30484515 PMCID: PMC6248252 DOI: 10.5935/abc.20180215
MicroRNAs in cardiovascular disease.
P Gurha. 2016. PMID: 26885771 DOI: 10.1097/HCO.0000000000000280
MicroRNAs in cardiovascular disease.
T Barwari, A Joshi, M Mayr. 2016. PMID: 27931616 DOI: 10.1016/j.jacc.2016.09.945
The role of miRNAs in cardiovascular disease risk factors.
JNJ Buie, AJ Goodwin, JA Cook, PV Halushka, H Fan. 2016. PMID: 27693002 PMCID: PMC5125538 DOI: 10.1016/j.atherosclerosis.2016.09.067
The Role of Alternative Toxicological Trials in Drug Discovery Programs. The Case of Caenorhabditis elegans and Other Methods.
LV Augsten, GM das Neves, et al. 2022. PMID: 35352642 DOI: 10.2174/0929867329666220329190825
Drug discovery: Insights from the invertebrate Caenorhabditis elegans.
S Giunti, N Andersen, D Rayes, et al. 2021. PMID: 33641258 PMCID: PMC7916527 DOI: 10.1002/prp2.721
Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths.
R Bauer, I Zafra, C Graham, et al. 2021. PMID: 34370008 PMCID: PMC8380043 DOI: 10.1242/dmm.049010
Drug discovery technologies: Caenorhabditis elegans as a model for anthelmintic therapeutics.
D Sepúlveda‐Crespo, RM Reguera, et al. 2020. PMID: 32166776 DOI: 10.1002/med.21668
Caenorhabditis elegans in anthelmintic research–Old model, new perspectives.
SR Hahnel, CM Dilks, I Heisler, EC Andersen, et al. 2020. DOI: 10.1016/j.ijpddr.2020.09.005
Caenorhabditis elegans as a model animal for investigating fungal pathogenesis.
M Madende, J Albertyn, O Sebolai, CH Pohl. 2020. PMID: 31555911 DOI: 10.1007/s00430-019-00635-4
Caenorhabditis elegans: nature and nurture gift to nematode parasitologists.
G Salinas, G Risi. 2018. PMID: 29208057 DOI: 10.1017/S0031182017002165
C. elegans as model for drug discovery.
M Carretero, GM Solis, M Petrascheck. 2017. PMID: 28137208 DOI: 10.2174/1568026617666170131114401
An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs.
W Kim, GL Hendricks, K Lee, et al. 2017. PMID: 28402221 DOI: 10.1080/17460441.2017.1319358
Drug discovery in fish, flies, and worms.
K Strange. 2017. PMID: 28053067 PMCID: PMC5886320 DOI: 10.1093/ilar/ilw034
Caenorhabditis elegans for rare disease modeling and drug discovery: strategies and strengths.
R Bauer, I Zafra, C Graham, et al. 2021. PMID: 34370008 PMCID: PMC8380043 DOI: 10.1242/dmm.049010
Caenorhabditis elegans as a model system for human diseases.
M Markaki, N Tavernarakis. 2020. PMID: 31951916 DOI: 10.1016/j.copbio.2019.12.011
Caenorhabditis elegans as a Useful Model for Studying Aging Mutations.
S Zhang, F Li, T Zhou, G Wang, Z Li. 2020. PMID: 33123086 PMCID: PMC7570440 DOI: 10.3389/fendo.2020.554994
Caenorhabditis elegans as a model system for target identification and drug screening against neurodegenerative diseases.
L Ma, Y Zhao, Y Chen, B Cheng, A Peng, et al. 2018. PMID: 29208474 DOI: 10.1016/j.ejphar.2017.11.051
What Can We Learn About Human Disease from the Nematode C. elegans?
J Apfeld, S Alper. 2018. PMID: 29423793 PMCID: PMC6391162 DOI: 10.1007/978-1-4939-7471-9_4
A simple answer to complex questions: Caenorhabditis elegans as an experimental model for examining the DNA damage response and disease genes.
M Rieckher, A Bujarrabal, MA Doll, et al. 2018. PMID: 28463453 PMCID: PMC5562273 DOI: 10.1002/jcp.25979
Caenorhabditis elegans as a model system for target identification and drug screening against neurodegenerative diseases.
L Ma, Y Zhao, Y Chen, B Cheng, A Peng, et al. 2018. PMID: 29208474 DOI: 10.1016/j.ejphar.2017.11.051
Genetic kidney diseases: Caenorhabditis elegans as model system.
A Ganner, E Neumann-Haefelin. 2017. PMID: 28484847 DOI: 10.1007/s00441-017-2622-z
Genetic variation in neurodegenerative diseases and its accessibility in the model organism Caenorhabditis elegans.
YA Wang, JE Kammenga, et al. 2017. PMID: 28545550 PMCID: PMC5445269 DOI: 10.1186/s40246-017-0108-4
Mechanisms of aging-related proteinopathies in Caenorhabditis elegans.
DK Kim, TH Kim, SJ Lee. 2016. PMID: 27713398 PMCID: PMC5099420 DOI: 10.1038/emm.2016.109
Drug discovery: Insights from the invertebrate Caenorhabditis elegans.
S Giunti, N Andersen, D Rayes, et al. 2021. PMID: 33641258 PMCID: PMC7916527 DOI: 10.1002/prp2.721
Immunometabolism in Caenorhabditis elegans.
SM Anderson, R Pukkila-Worley. 2020. PMID: 33031414 PMCID: PMC7544110 DOI: 10.1371/journal.ppat.1008897
Drug discovery technologies: Caenorhabditis elegans as a model for anthelmintic therapeutics.
D Sepúlveda‐Crespo, RM Reguera, et al. 2020. PMID: 32166776 DOI: 10.1002/med.21668
Caenorhabditis elegans as a model animal for investigating fungal pathogenesis.
M Madende, J Albertyn, O Sebolai, CH Pohl. 2020. PMID: 31555911 DOI: 10.1007/s00430-019-00635-4
Caenorhabditis elegans as a Model Host to Monitor the Candida Infection Processes.
AB Elkabti, L Issi, RP Rao. 2018. PMID: 30405043 PMCID: PMC6309157 DOI: 10.3390/jof4040123
What Can We Learn About Human Disease from the Nematode C. elegans?
J Apfeld, S Alper. 2018. PMID: 29423793 PMCID: PMC6391162 DOI: 10.1007/978-1-4939-7471-9_4
Bacteria and bacterial products: Foe and friends to Caenorhabditis elegans.
F Khan, S Jain, SF Oloketuyi. 2018. PMID: 30172296 DOI: 10.1016/j.micres.2018.06.012
An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs.
W Kim, GL Hendricks, K Lee. et al. 2017. PMID: 28402221 DOI: 10.1080/17460441.2017.1319358
Caenorhabditis elegans as a model for understanding ROS function in physiology and disease.
A Miranda-Vizuete, EA Veal. 2017. PMID: 28193593 PMCID: PMC5304259 DOI: 10.1016/j.redox.2016.12.020
Surveillance Immunity: An Emerging Paradigm of Innate Defense Activation in Caenorhabditis elegans.
R Pukkila-Worley. 2016. PMID: 27631629 PMCID: PMC5025020 DOI: 10.1371/journal.ppat.1005795
Application of Caenorhabditis elegans in the evaluation of food nutrition: A review.
Q Li, M Xiao, N Li, W Cai, C Zhao, B Liu, F Zeng. 2023. PMID: 35939623 PMCID: PMC9361767 DOI: 10.1080/19490976.2022.2107386
Regulation and functions of membrane lipids: insights from Caenorhabditis elegans.
M Koyiloth, SN Gummadi. 2022. DOI: 10.1016/j.bbadva.2022.100043
Lipid metabolism and ageing in Caenorhabditis elegans: a complex interplay.
T Rubio-Tomás, N Tavernarakis. 2022. PMID: 36048312 DOI: 10.1007/s10522-022-09989-4
Drug discovery: Insights from the invertebrate Caenorhabditis elegans.
S Giunti, N Andersen, D Rayes, et al. 2021. PMID: 33641258 PMCID: PMC7916527 DOI: 10.1002/prp2.721
An overview of the insulin signaling pathway in model organisms Drosophila melanogaster and Caenorhabditis elegans.
SG Biglou, WG Bendena, I Chin-Sang. 2021. PMID: 34450203 DOI: 10.1016/j.peptides.2021.170640
Effects of High Dietary Carbohydrate and Lipid Intake on the Lifespan of C. elegans.
B Franco-Juárez, S Gómez-Manzo, et al. 2021.
Caenorhabditis elegans as a model system for human diseases.
M Markaki, N Tavernarakis. 2020. PMID: 34572007 PMCID: PMC8465757 DOI: 10.3390/cells10092359
C. elegans to model autophagy-related human disorders.
SQ Wong, AV Kumar, J Mills, LR Lapierre. 2020. PMID: 32620247 DOI: 10.1016/bs.pmbts.2020.01.007
Forward and reverse genetics approaches to uncover metabolic aging pathways in Caenorhabditis elegans.
AW Gao, J uit de Bos, MG Sterken, et al. 2018. PMID: 28919364 DOI: 10.1016/j.bbadis.2017.09.006
C. elegans as a model organism for human mitochondrial associated disorders.
S Maglioni, N Ventura. 2016. PMID: 26906059 DOI: 10.1016/j.mito.2016.02.003
Using Caenorhabditis elegans to model therapeutic interventions of neurodegenerative diseases targeting microbe-host interactions.
C Wang, C Zheng. 2022. PMID: 35571084 PMCID: PMC9096141 DOI: 10.3389/fphar.2022.875349
Iron overload and neurodegenerative diseases: What can we learn from Caenorhabditis elegans?
AC Martins, MB Virgolini, AA Tinkov, et al. 2022. PMID: 35990536 PMCID: PMC9390093 DOI: 10.1177/23978473221091852
Invited review: Unearthing the mechanisms of age-related neurodegenerative disease using Caenorhabditis elegans.
AN Hayden, E Leptich, RN Arey, et al. 2022. PMID: 35176489 DOI: 10.1016/j.cbpa.2022.111166
Caenorhabditis elegans as a model system for studying aging-associated neurodegenerative diseases.
KM Van Pelt, MC Truttmann. 2020. PMID: 34327290 PMCID: PMC8317484 DOI: 10.1016/j.tma.2020.05.001
Modeling neurodegeneration in Caenorhabditis elegans.
KA Caldwell, CW Willicott, et al. 2020. PMID: 33106318 PMCID: PMC7648605 DOI: 10.1242/dmm.046110
Caenorhabditis elegans as a model system for target identification and drug screening against neurodegenerative diseases.
L Ma, Y Zhao, Y Chen, B Cheng, A Peng, et al. 2018. PMID: 29208474 DOI: 10.1016/j.ejphar.2017.11.051
Genetic variation in neurodegenerative diseases and its accessibility in the model organism Caenorhabditis elegans.
YA Wang, JE Kammenga, et al. 2017. PMID: 28545550 PMCID: PMC5445269 DOI: 10.1186/s40246-017-0108-4
Caenorhabditis elegans models of tauopathy.
GJ Pir, B Choudhary, E Mandelkow. 2017. PMID: 29191965 DOI: 10.1096/fj.201701007
C. elegans as a model system to accelerate discovery for Parkinson disease.
BA Martinez, KA Caldwell, GA Caldwell. 2017.
Mechanisms of aging-related proteinopathies in Caenorhabditis elegans.
DK Kim, TH Kim, SJ Lee. 2016. PMID: 28242493 DOI: 10.1016/j.gde.2017.02.011
Multifaceted effects of aluminum in neurodegenerative diseases: A review.
S Maya, T Prakash, KD Madhu, D Goli. 2016. PMID: 27479193 DOI: 10.1016/j.biopha.2016.07.035
The InVivo Biosystems Newsletter is delivered to your inbox bi-weekly,
giving you all of the latest company updates, industry news, and more.
An expert in CRISPR genome editing, InVivo Biosystems creates custom genome-edited C. elegans and zebrafish models to enable aging, developmental, and disease studies. Our unique in vivo platforms and technologies bridge the gap between cells and mice.